Antiverse: Series ADevelops therapeutic antibodies for challenging disease targets using AI-driven techbioOct 4, 2026RoundOSAntiverseCompany profile and funding historySourcesbusinesswire.comMore in HealthtechMetriport · Series AProFound Therapeutics · StrategicArintra · Series BAISeries A · AIBiotechUnited KingdomEnterprise softwareHealthtechEuropeSeries A